On October 2, 2024, the Food and Drug Administration (FDA) announced that it removed tirzepatide injection, a glucagon-like peptide 1 receptor agonist (GLP-1 RA) marketed by Eli Lilly, from its drug shortages list. Tirzepatide is the…

On September 20th, 2024, the U.S. Food and Drug Administration (FDA) approved MedImmune and AstraZeneca's FluMist® (influenza virus vaccine) for self-administration. FluMist® is…

In the first quarter of 2024, The American Society of Health-System Pharmacists (ASHP) reported an estimated 323 active drug shortages, slightly exceeding the previous record of 320 shortages set in 2014. In light of…

The rapidly growing popularity of glucagon-like peptide 1 (GLP-1) receptor agonists for use in weight loss has led to widespread shortages of…

Through June 30, 2024, the FDA approved 27 novel pharmaceutical products for use in the United States. While 2023 was a record-breaking year with 72 novel approvals, this year is expected to approach that number. Of the novel approval’s…